TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12145222

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat diet (M) with 9% energy as C18:1cis (oleic acid)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Saturated fat diet (S) with 9% energy as palmitic acid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Trans fatty acid diet (T) with 9% energy as C18:1trans
Number of subjects: 25
Study: 9527194

Group type: EXPERIMENTAL
Intervention: DIP + APR
Number of subjects: 115

Group type: COMPARATOR
Intervention: DIP
Number of subjects: 115
Study: 7629898

Group type: EXPERIMENTAL
Intervention: Oral buffered deferoxamine solution (5 mg/kg elemental iron)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control phase (5 mg/kg elemental iron alone)
Number of subjects: 7
Study: 2624725

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 779516

Group type: EXPERIMENTAL
Intervention: Maltose treatment (drinks sweetened with maltose 2 hours before operation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Starved group (control)
Number of subjects: 50
Study: 31641203

Group type: EXPERIMENTAL
Intervention: TRT + RT
Number of subjects: 22

Group type: COMPARATOR
Intervention: TRT
Number of subjects: 22
Study: 30879908

Group type: EXPERIMENTAL
Intervention: Forced-air warming system group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluid group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 28399624

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study: 25925033

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (3mg/kg infused over 1h)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23021990

Group type: EXPERIMENTAL
Intervention: Fatigued condition (after performing repeated sit‐to‐stand movement)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rested condition
Number of subjects: 30
Study: 21756299

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group intervention for children with CI (called 'Op Koers')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group intervention for children with CI combined with a parent program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 19629674

Group type: COMPARATOR
Intervention: hCG
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate 0.15 mg)
Number of subjects: 44
Study: 16984503

Group type: EXPERIMENTAL
Intervention: MMX mesalazine 1.2 g/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MMX mesalazine 2.4 g/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MMX mesalazine 4.8 g/day
Number of subjects: 38
Study: 12532113

Group type: EXPERIMENTAL
Intervention: Diet intervention (omega-3 fatty acids)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: HDM avoidance intervention
Number of subjects: 616
Study: 11271083

Group type: EXPERIMENTAL
Intervention: CPAP (5‐7.5 cmH2O)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 9
Study: 10160021

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2069772

Group type: EXPERIMENTAL
Intervention: 80 mEq KCl/day
Number of subjects: 0
Study: 6827873

Group type: EXPERIMENTAL
Intervention: Category rating scale with evenly distributed values across the response scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category rating scale with items from the top of the scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category rating scale with items with low values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category rating scale with items with low and high values (but not middle range)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category rating scale with items with medium values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimuli that are not health case descriptions with poorly defined response continuum
Number of subjects: 0
Study: 31470599

Group type: EXPERIMENTAL
Intervention: 600 mg of non-animal chondroitin sulfate daily for 12 weeks
Number of subjects: 60
Study: 29327032

Group type: EXPERIMENTAL
Intervention: Cotton pad filtration
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Centrifugation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sedimentation
Number of subjects: 63
Study: 26699729

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25022777

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 50
Study: 22171907

Group type: EXPERIMENTAL
Intervention: Patient Education Programme for Parkinson's disease (PEPP)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Caregivers of PD patients
Number of subjects: 64
Study: 20921313

Group type: EXPERIMENTAL
Intervention: Raltegravir with antacid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Raltegravir alone
Number of subjects: 12
Study: 17931943

Group type: EXPERIMENTAL
Intervention: ProTaper Universal Tulsa retreatment system
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hedström files with chloroform
Number of subjects: 45

Group type: COMPARATOR
Intervention: K-flex files
Number of subjects: 45
Study: 16361918

Group type: EXPERIMENTAL
Intervention: 0 to 5 units of PRBCs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 6 to 10 units of PRBCs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: greater than 10 units of PRBCs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: More units of PRBCs during the first 24 hours
Number of subjects: 102
Study: 11975149

Group type: EXPERIMENTAL
Intervention: Single-use learning of transformations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed-use learning of transformations
Number of subjects: 0
Study: 9596181

Group type: EXPERIMENTAL
Intervention: Monopolar stimulation modes
Number of subjects: 5

Group type: COMPARATOR
Intervention: Bipolar stimulation mode
Number of subjects: 5
Study: 7816379

Group type: EXPERIMENTAL
Intervention: 99Tcm-MAG3 renogram deconvolution in healthy kidneys
Number of subjects: 78

Group type: COMPARATOR
Intervention: 99Tcm-MAG3 renogram deconvolution in normal functioning kidney grafts
Number of subjects: 78
Study: 3399331

Group type: COMPARATOR
Intervention: 5% bandwidth group (BW5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10% bandwidth group (BW10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (KR)
Number of subjects: 0
Study: 31925185

Group type: EXPERIMENTAL
Intervention: Genetically predicted insulin (per pmol/L higher insulin)
Number of subjects: 392010
Study: 28449232

Group type: EXPERIMENTAL
Intervention: 0.35 mg GSK2881078 (in women)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.05 mg, 0.2 mg, 0.08 mg, 0.24 mg, 0.48 mg, 0.75 mg GSK2881078 (in men)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (in women)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (in men)
Number of subjects: 99
Study: 26381232

Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 23398594

Group type: EXPERIMENTAL
Intervention: Arm 1, 60 CGE/20 fractions/5 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Arm 2, 54 CGE/15 fractions/5 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Arm 3, 47 CGE/10 fractions/5 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Arm 4, 35 CGE/5 fractions/2.5 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Arm 5, 35 CGE/5 fractions/5 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 82
Study: 21723443

Group type: EXPERIMENTAL
Intervention: Black women with PCOS
Number of subjects: 242
Study: 20017932

Group type: EXPERIMENTAL
Intervention: ACEI (Quinapril) or Statins (Atorvastatin) or combination therapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 16761149

Group type: EXPERIMENTAL
Intervention: Autologous transfusion drain (Bellovac)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard suction drain (Redivac)
Number of subjects: 104
Study: 15152893

Group type: EXPERIMENTAL
Intervention: Montelukast (CysLTs type‐1 receptor antagonist)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 11
Study: 11700185

Group type: EXPERIMENTAL
Intervention: Granular formulation of the insect growth regulator pyriproxyfen at a target dose of 0.01 mg a.i./litre
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control villages (not treated with pyriproxyfen)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Granular formulation of the insect growth regulator pyriproxyfen
Number of subjects: 8
Study: 9383759

Group type: EXPERIMENTAL
Intervention: Sealant (Delton)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Fluoride Varnish (Duraphat)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 314
Study: 8197772

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Continuous normothermic peritoneal perfusion (CNPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (gastric surgery without perfusion)
Number of subjects: 58
Study: 2839628

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily (n = 16)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg twice daily (n = 15)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg enalapril and 25 mg hydrochlorothiazide twice daily, n = 6)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination therapy after 8 additional weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination therapy after one year
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 37
Study: 2232494

Group type: EXPERIMENTAL
Intervention: Ingestion of a large inorganic acid load
Number of subjects: 0
Study: 4937034

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 10% lignocaine
Number of subjects: 10
Study: 31870692

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 31395122

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 923

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 923
Study: 27806666

Group type: EXPERIMENTAL
Intervention: Education group (n=68): face-to-face training session, three phone sessions, and a booklet
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (n=68): routine postpartum care on days 1‐3, 10‐15 and 42‐60
Number of subjects: 136
Study: 25593120

Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 854
Study: 23673908

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21422412

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 3449

Group type: COMPARATOR
Intervention: Tamoxifen for 2 years
Number of subjects: 3449
Study: 19019444

Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Initial medicine
Number of subjects: 607
Study: 17980734

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 826
Study: 15254884

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Sialic acid
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 86
Study: 12830543

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 9663538

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 413

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 413
Study: 7944835

Group type: EXPERIMENTAL
Intervention: Active antihypertensive drug therapy (12.5 to 25 mg of chlorthalidone for step 1; 25 to 50 mg of atenolol for step 2; or 0.05 to 0.10 mg of reserpine if atenolol was contraindicated)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4736
Study: 3065740

Group type: EXPERIMENTAL
Intervention: High dose continuous chlorambucil (regimen A)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Intermittent chlorambucil plus prednisone (regimen B)
Number of subjects: 279
Study: 30352838

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg daily
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Fenretinide 200 mg daily
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Combination of Tamoxifen and Fenretinide
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 27054677

Group type: EXPERIMENTAL
Intervention: Passive cycling
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 24
Study: 25248814

Group type: EXPERIMENTAL
Intervention: Elevated baseline IGFBP7 concentrations
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: IGFBP7 concentrations
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: More time spent with elevated IGFBP7 concentrations
Number of subjects: 124
Study: 22451568

Group type: EXPERIMENTAL
Intervention: Increased viewing time for mammography cases
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High confidence in assessment
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Lower confidence in assessment
Number of subjects: 119
Study: 19883392

Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18084173

Group type: EXPERIMENTAL
Intervention: Gait trainer (PBWS), 40 minutes sessions, 5 times a week, for 5 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bobath method, 40 minutes sessions, 5 times a week, for 5 weeks
Number of subjects: 40
Study: 16118090

Group type: EXPERIMENTAL
Intervention: Calcium carbonate and vitamin D3
Number of subjects: 26
Study: 12173362

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenously) during normoglycemia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg intravenously) during hyperglycemia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo during normoglycemia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo during hyperglycemia
Number of subjects: 12
Study: 10592403

Group type: EXPERIMENTAL
Intervention: Gentian violet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Liquor carbonis detergens (tar preparation)
Number of subjects: 21
Study: 8696696

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Spiral computed tomography (SCT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Examination under anaesthesia (EUA)
Number of subjects: 38
Study: 1656738

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once on day 1 followed by 250 mg once daily for 4 days
Number of subjects: 242

Group type: COMPARATOR
Intervention: Penicillin V 250 mg every 6 hours for 10 days
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 242

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 242
Study: 6311790

Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 87

Group type: COMPARATOR
Intervention: Gentamicin plus cefotaxime
Number of subjects: 87
Study: 29974299

Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 190

Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 190
Study: 27067478

Group type: EXPERIMENTAL
Intervention: Riociguat (2.5 mg three times per day)
Number of subjects: 237
Study: 25240461

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs-containing fish oil (average DHA and EPA doses of 72.9 and 117.1 mg/kg b.w./day) for 12 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated RTT group (Control)
Number of subjects: 24
Study: 23133592

Group type: EXPERIMENTAL
Intervention: Choline intake of 480 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nonpregnant women (n=21)
Number of subjects: 26
Study: 20212029

Group type: EXPERIMENTAL
Intervention: Collaborative care involving physicians and pharmacists
Number of subjects: 225

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 225
Study: 17392142

Group type: EXPERIMENTAL
Intervention: Standard nutritional intervention and health education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple health education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple nutritional intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 15734767

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2159
Study: 12488154

Group type: EXPERIMENTAL
Intervention: Positive sentinel lymph node (SLN) biopsy
Number of subjects: 1183

Group type: COMPARATOR
Intervention: Negative sentinel lymph node (SLN) biopsy
Number of subjects: 1183
Study: 10221638

Group type: EXPERIMENTAL
Intervention: Nefazodone (n = 65)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 131
Study: 8556698

Group type: EXPERIMENTAL
Intervention: Growth hormone and insulin-like growth factor 1 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone replacement
Number of subjects: 0
Study: 2141494

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) and Medroxyprogesterone acetate (MPA)
Number of subjects: 72
Study: 733601

Group type: EXPERIMENTAL
Intervention: One fraction of 2100-2250 R
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Four fractions of 1000-4000 R during 4 days
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Eight fractions of 600-4800 R during 9 days
Number of subjects: 368
Study: 30398382

Group type: EXPERIMENTAL
Intervention: No drain after RARP (SG)
Number of subjects: 112
Study: 31651365

Group type: EXPERIMENTAL
Intervention: Alcohol use among pregnant women
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Abortion history
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Pre pregnancy alcohol use
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Mental distress
Number of subjects: 718
Study: 29056418

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (25 μg kg−1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (25 μg kg−1) with MK‐467 (600 μg kg−1)
Number of subjects: 6
Study: 26037292

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose before PCI
Number of subjects: 213

Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose at the time of PCI
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 213

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 213
Study: 24209894

Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20881877

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=97)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control (usual care, n=88)
Number of subjects: 185
Study: 19921566

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision (LTME)
Number of subjects: 198
Study: 17682674

Group type: EXPERIMENTAL
Intervention: Token test (Orgass version, 1976)
Number of subjects: 200
Study: 15365929

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine/1.5 microg/kg of fentanyl with 5 microg/mL of epinephrine (group IPBF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 5 microg/mL of epinephrine (group IPB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline (group IPS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (group IVF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interpleural saline (group IPS)
Number of subjects: 60
Study: 11830753

Group type: EXPERIMENTAL
Intervention: Cilostazol (Pletal®)
Number of subjects: 8
Study: 9757963

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 0
Study: 8983590

Group type: EXPERIMENTAL
Intervention: Low fluoroscopic current (0.5 mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fluoroscopic current (1.5 mA)
Number of subjects: 0
Study: 2135682

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6453849

Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate in aqueous-alcohol vehicle
Number of subjects: 29

Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 29
Study: 31282363

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Number of subjects: 647

Group type: COMPARATOR
Intervention: Eye drops
Number of subjects: 647
Study: 28091776

Group type: EXPERIMENTAL
Intervention: Nasal masks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Binasal prongs
Number of subjects: 72
Study: 25885964

Group type: EXPERIMENTAL
Intervention: LISA (less invasive surfactant administration) group, n=47
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intubation group, n=43
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LISA group, n=47
Number of subjects: 90